Aaron Cowen’s Benitec Biopharma BNTC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$155M Hold
11,548,351
2.83% 7
2026
Q1
$123M Hold
11,548,351
3.14% 7
2025
Q4
$156M Buy
11,548,351
+1,671,845
+17% +$23.1M 3.19% 4
2025
Q3
$139M Hold
9,876,506
3.55% 3
2025
Q2
$116M Hold
9,876,506
3.48% 7
2025
Q1
$128M Buy
9,876,506
+916,497
+10% +$11.1M 4.77% 4
2024
Q4
$113M Buy
8,960,009
+130,956
+1% +$1.41M 3.86% 6
2024
Q3
$81.1M Buy
8,829,053
+7,137,763
+422% +$63.9M 2.6% 9
2024
Q2
$11.8M Buy
1,691,290
+1,487,070
+728% +$11M 0.43% 47
2024
Q1
$1.07M Hold
204,220
0.04% 86
2023
Q4
$660K Hold
204,220
0.03% 82
2023
Q3
$617K Buy
204,220
+158,985
+351% +$494K 0.03% 82
2023
Q2
$3.12M Hold
45,235
0.17% 66
2023
Q1
$161K Hold
45,235
0.01% 94
2022
Q4
$131K Hold
45,235
0.01% 88
2022
Q3
$286K Hold
45,235
0.01% 71
2022
Q2
$892K Hold
45,235
0.03% 85
2022
Q1
$1.8M Hold
45,235
0.05% 76
2021
Q4
$2.02M Hold
45,235
0.04% 80
2021
Q3
$2.75M Hold
45,235
0.05% 90
2021
Q2
$3.27M Buy
+45,235
New +$3.54M 0.05% 99

Other funds holding BNTC

Aaron Cowen's BNTC Position: Q2 2026 in Review

Aaron Cowen held its Benitec Biopharma (BNTC) position steady in Q2 2026 at 11,548,351 shares worth $155M. The position accounts for 2.83% of the portfolio, ranked #7.

Aaron Cowen first reported a position in BNTC in Q2 2021 and has held it in 21 quarters since. The position peaked at $156M in Q4 2025. 86 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

  • Aaron Cowen held 11,548,351 shares of Benitec Biopharma worth $155M as of Q2 2026.
  • Aaron Cowen left its Benitec Biopharma share count unchanged in Q2 2026.
  • Benitec Biopharma made up 2.83% of Aaron Cowen's portfolio in Q2 2026, its #7 holding.
  • Aaron Cowen first reported a position in Benitec Biopharma in Q2 2021 and has held it in 21 quarters since.
  • Aaron Cowen's Benitec Biopharma position peaked at $156M in Q4 2025.
  • 86 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Suvretta Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.